The findings of this study indicate that the third-generation bisphosphonates have positive effect on bone mineral density of patients who are suspected to or have suffered from bone loss, osteopenia, or osteoporosis due to the treatment of aromatase inhibitors in hormone responsive breast cancer. Here, CYP19A1 is linked to osteoporosis.